Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance

Jurgen Bernd Bulitta, Olanrewaju Okusanya, Alan Forrest, Sujata Bhavnani, Kay Clark, J Gordon Still, Prabhavathi Fernandes, Paul Ambrose

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)

Abstract

The objectives of this analysis were to develop a population pharmacokinetic (PK) model to describe the absorption and disposition of fusidic acid after single and multiple doses and to determine the effect of food on the rate and extent of bioavailability. Plasma PK data from three phase 1 studies (n = 75; n = 14 with and without food) in which healthy subjects received sodium fusidate (500 to 2,200 mg) as single or multiple oral doses every 8 h (q8h) or q12h for up to 7 days were modeled using S-ADAPT (MCPEM algorithm). Accumulation of fusidic acid after multiple doses was more than that predicted based on single-dose data. The PK of fusidic acid was best described using a time-dependent mixed-order absorption process, two disposition compartments, and a turnover process to describe the autoinhibition of clearance. The mean total clearance ( coefficient of variation) was 1.28 liters/h (33 ) and the maximum extent of autoinhibition was 71.0 , with a 50 inhibitory concentration (IC 50) of 46.3 mg/liter (36 ). Food decreased the extent of bioavailability by 18 . As a result of the autoinhibition of clearance, steady state can be achieved earlier with dosing regimens that contain higher doses (after 8 days for 750 mg q12h and 1 day for 1,500 mg q12h on day 1 followed by 600 mg q12h versus 3 weeks for 500 mg q12h). Given that large initial doses autoinhibit the clearance of fusidic acid, this characteristic provides a basis for the administration of front-loaded dosing regimens of sodium fusidate which would allow for effective concentrations to be achieved early in therapy.
Original languageEnglish
Pages (from-to)498 - 507
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number1
DOIs
Publication statusPublished - 2013

Cite this

Bulitta, Jurgen Bernd ; Okusanya, Olanrewaju ; Forrest, Alan ; Bhavnani, Sujata ; Clark, Kay ; Still, J Gordon ; Fernandes, Prabhavathi ; Ambrose, Paul. / Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 1. pp. 498 - 507.
@article{e3662c9e44a3435eb48b431687b966c8,
title = "Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance",
abstract = "The objectives of this analysis were to develop a population pharmacokinetic (PK) model to describe the absorption and disposition of fusidic acid after single and multiple doses and to determine the effect of food on the rate and extent of bioavailability. Plasma PK data from three phase 1 studies (n = 75; n = 14 with and without food) in which healthy subjects received sodium fusidate (500 to 2,200 mg) as single or multiple oral doses every 8 h (q8h) or q12h for up to 7 days were modeled using S-ADAPT (MCPEM algorithm). Accumulation of fusidic acid after multiple doses was more than that predicted based on single-dose data. The PK of fusidic acid was best described using a time-dependent mixed-order absorption process, two disposition compartments, and a turnover process to describe the autoinhibition of clearance. The mean total clearance ( coefficient of variation) was 1.28 liters/h (33 ) and the maximum extent of autoinhibition was 71.0 , with a 50 inhibitory concentration (IC 50) of 46.3 mg/liter (36 ). Food decreased the extent of bioavailability by 18 . As a result of the autoinhibition of clearance, steady state can be achieved earlier with dosing regimens that contain higher doses (after 8 days for 750 mg q12h and 1 day for 1,500 mg q12h on day 1 followed by 600 mg q12h versus 3 weeks for 500 mg q12h). Given that large initial doses autoinhibit the clearance of fusidic acid, this characteristic provides a basis for the administration of front-loaded dosing regimens of sodium fusidate which would allow for effective concentrations to be achieved early in therapy.",
author = "Bulitta, {Jurgen Bernd} and Olanrewaju Okusanya and Alan Forrest and Sujata Bhavnani and Kay Clark and Still, {J Gordon} and Prabhavathi Fernandes and Paul Ambrose",
year = "2013",
doi = "10.1128/AAC.01354-12",
language = "English",
volume = "57",
pages = "498 -- 507",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "American Society for Microbiology",
number = "1",

}

Bulitta, JB, Okusanya, O, Forrest, A, Bhavnani, S, Clark, K, Still, JG, Fernandes, P & Ambrose, P 2013, 'Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance', Antimicrobial Agents and Chemotherapy, vol. 57, no. 1, pp. 498 - 507. https://doi.org/10.1128/AAC.01354-12

Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance. / Bulitta, Jurgen Bernd; Okusanya, Olanrewaju; Forrest, Alan; Bhavnani, Sujata; Clark, Kay; Still, J Gordon; Fernandes, Prabhavathi; Ambrose, Paul.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 1, 2013, p. 498 - 507.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance

AU - Bulitta, Jurgen Bernd

AU - Okusanya, Olanrewaju

AU - Forrest, Alan

AU - Bhavnani, Sujata

AU - Clark, Kay

AU - Still, J Gordon

AU - Fernandes, Prabhavathi

AU - Ambrose, Paul

PY - 2013

Y1 - 2013

N2 - The objectives of this analysis were to develop a population pharmacokinetic (PK) model to describe the absorption and disposition of fusidic acid after single and multiple doses and to determine the effect of food on the rate and extent of bioavailability. Plasma PK data from three phase 1 studies (n = 75; n = 14 with and without food) in which healthy subjects received sodium fusidate (500 to 2,200 mg) as single or multiple oral doses every 8 h (q8h) or q12h for up to 7 days were modeled using S-ADAPT (MCPEM algorithm). Accumulation of fusidic acid after multiple doses was more than that predicted based on single-dose data. The PK of fusidic acid was best described using a time-dependent mixed-order absorption process, two disposition compartments, and a turnover process to describe the autoinhibition of clearance. The mean total clearance ( coefficient of variation) was 1.28 liters/h (33 ) and the maximum extent of autoinhibition was 71.0 , with a 50 inhibitory concentration (IC 50) of 46.3 mg/liter (36 ). Food decreased the extent of bioavailability by 18 . As a result of the autoinhibition of clearance, steady state can be achieved earlier with dosing regimens that contain higher doses (after 8 days for 750 mg q12h and 1 day for 1,500 mg q12h on day 1 followed by 600 mg q12h versus 3 weeks for 500 mg q12h). Given that large initial doses autoinhibit the clearance of fusidic acid, this characteristic provides a basis for the administration of front-loaded dosing regimens of sodium fusidate which would allow for effective concentrations to be achieved early in therapy.

AB - The objectives of this analysis were to develop a population pharmacokinetic (PK) model to describe the absorption and disposition of fusidic acid after single and multiple doses and to determine the effect of food on the rate and extent of bioavailability. Plasma PK data from three phase 1 studies (n = 75; n = 14 with and without food) in which healthy subjects received sodium fusidate (500 to 2,200 mg) as single or multiple oral doses every 8 h (q8h) or q12h for up to 7 days were modeled using S-ADAPT (MCPEM algorithm). Accumulation of fusidic acid after multiple doses was more than that predicted based on single-dose data. The PK of fusidic acid was best described using a time-dependent mixed-order absorption process, two disposition compartments, and a turnover process to describe the autoinhibition of clearance. The mean total clearance ( coefficient of variation) was 1.28 liters/h (33 ) and the maximum extent of autoinhibition was 71.0 , with a 50 inhibitory concentration (IC 50) of 46.3 mg/liter (36 ). Food decreased the extent of bioavailability by 18 . As a result of the autoinhibition of clearance, steady state can be achieved earlier with dosing regimens that contain higher doses (after 8 days for 750 mg q12h and 1 day for 1,500 mg q12h on day 1 followed by 600 mg q12h versus 3 weeks for 500 mg q12h). Given that large initial doses autoinhibit the clearance of fusidic acid, this characteristic provides a basis for the administration of front-loaded dosing regimens of sodium fusidate which would allow for effective concentrations to be achieved early in therapy.

UR - http://aac.asm.org/content/57/1/498

U2 - 10.1128/AAC.01354-12

DO - 10.1128/AAC.01354-12

M3 - Article

VL - 57

SP - 498

EP - 507

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 1

ER -